TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 23905372
Drug: Pengyan Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pengyan Pill (PP)
Study: 19234829
Drug: Individualized recruitment
Normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Individualized recruitment maneuver (RM) with pressure equal to 15 ml x real body weight/Cdyn + PEEP for 15 s
Study: 15277416
Drug: Pioglitazone (30-mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pioglitazone (30-mg tablet of Actos)
Study: 15277416
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy with GLP-1 and pioglitazone
Study: 15277416
Drug: Saline therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline therapy
Study: 23954500
Drug: 6.5mg prasterone
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6.5mg prasterone (DHEA) administered intravaginally daily
Study: 18090394
Drug: Differential adherence
Approvals — FDA: no, EMA: no, PMDA: no
Description: Differential adherence (any antiretroviral medication)
Study: 10774095
Drug: Goserelin acetate
Normalized name: Goserelin Acetate
DrugBank: Goserelin (DB00014)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Goserelin acetate (3.6 mg every 21 days)
Study: 3912026
Drug: Ibuprofen 2400
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ibuprofen 2400 mg (given in two or four equally divided daily doses)
Study: 3912026
Drug: Ibuprofen (twice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen (twice daily)
Study: 3912026
Drug: Ibuprofen (four
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen (four times daily)
Study: 31301627
Drug: Sunlight plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sunlight plus conventional vitamin D supplement (400IU/d)
Study: 31301627
Drug: Sunlight exposure
Normalized name: Bacillus anthracis strain V770-NP1-R antigens
DrugBank: Anthrax vaccine (DB11003)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sunlight exposure (7-14 h/week) plus conventional vitamin D supplement (400IU/d)
Study: 24813646
Drug: 120 mg
Normalized name: papain 120 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 120 mg ATP daily for 4 weeks
Study: 20211294
Drug: Apixaban 5
Normalized name: apixaban 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apixaban 5 mg twice daily (2.5 mg twice daily in selected patients)
Study: 22818021
Drug: Aspirin 81
Normalized name: aspirin 81 MG
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin 81 to 324 mg daily
Study: 16307657
Drug: Etanercept 50
Normalized name: etanercept 50 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etanercept 50 mg per week
Study: 12114351
Drug: Beclomethasone 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beclomethasone 100 microg/d plus zafirlukast 20 mg bid
Study: 12114351
Drug: Beclomethasone 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beclomethasone 100 microg/d plus theophylline 200 to 300 mg bid
Study: 10439754
Drug: Epidural infusion
Normalized name: epidural administration set EPIDURAL INFUSION SETS-PARAPHERNALIA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural infusion of 0.1% ropivacaine with 1 microgram/mL sufentanil (R + S)
Study: 10439754
Drug: Epidural infusion
Normalized name: epidural administration set EPIDURAL INFUSION SETS-PARAPHERNALIA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural infusion of 0.1% ropivacaine without sufentanil (R)
Study: 8560534
Drug: Ivermectin (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ivermectin (5 doses distributed every 6 months)
Study: 2518436
Drug: Various procedures
Normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Various procedures concerning the site of implantation and treatment of exocrine function
Study: 61224
Drug: Tolmetin sodium
Normalized name: Tolmetin Sodium
DrugBank: Tolmetin (DB00500)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tolmetin sodium (800-1600 mg daily for 12 weeks)
Study: 61224
Drug: Tolmetin sodium
Normalized name: Tolmetin Sodium
DrugBank: Tolmetin (DB00500)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tolmetin sodium (400-2400 mg daily for 2 years)
Study: 28244804
Drug: Pharmacogenetic testing
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacogenetic testing integrated into medication therapy management services
Study: 16456408
Drug: Proton pump
Normalized name: Proton pump inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Proton pump inhibitor + ranitidine
Study: 16456408
Drug: Proton pump
Normalized name: Proton pump inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Proton pump inhibitor + placebo
Study: 12207595
Drug: Isotretinoin gel
Normalized name: Isotretinoin
DrugBank: Isotretinoin (DB00982)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isotretinoin gel 0.05%
Study: 9707349
Drug: Epogam (evening
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epogam (evening primrose oil) - 6 capsules in the morning and 6 capsules in the evening
Study: 359254
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg oxyphenbutazone 3-times daily
Study: 27073000
Drug: HR-ADM plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: HR-ADM plus standard of care (SOC) applied weekly for up to 12 weeks
Study: 15517057
Drug: Psychodynamic group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psychodynamic group treatment (PGT)
Study: 30049729
Drug: Bubble nCPAP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bubble nCPAP and nebulised surfactant (200 mg/kg: poractant alfa)
Study: 25979614
Drug: 17-hydroxyprogesterone caproate
Normalized name: 6α-Methyl-17α-hydroxyprogesterone acetate
Approvals — FDA: no, EMA: no, PMDA: no
Description: 17-hydroxyprogesterone caproate (250 mg weekly intramuscular injections)
Study: 21312264
Drug: ONO-5334 50
Normalized name: ONO-5334
DrugBank: ONO-5334 (DB19206)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ONO-5334 50 mg twice daily
Study: 21719717
Drug: ONO-5334 100
Normalized name: ONO-5334
DrugBank: ONO-5334 (DB19206)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ONO-5334 100 mg once daily
Study: 21719717
Drug: ONO-5334 300
Normalized name: ONO-5334
DrugBank: ONO-5334 (DB19206)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ONO-5334 300 mg once daily
Study: 12763981
Drug: 50% reduction
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50% reduction in inhaled corticosteroid dose (stepdown)
Study: 12763981
Drug: No alteration
Approvals — FDA: no, EMA: no, PMDA: no
Description: No alteration to inhaled corticosteroid dose (control)
Study: 10678632
Drug: 375 mg
Normalized name: niacin 375 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 375 mg oral slow-release theophylline (250 mg if <70 kg) taken twice daily
Study: 10678632
Drug: Matched placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matched placebo tablet taken twice daily
Study: 9362433
Drug: Pamidronate (90
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pamidronate (90 mg) as a 4-hour infusion every 4 weeks for 21 cycles in addition to antimyeloma chemotherapy
Study: 8383639
Drug: Gorging pattern
Normalized name: benzocaine
DrugBank: Benzocaine (DB01086)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gorging pattern (2 meals daily)
Study: 8383639
Drug: Nibbling pattern
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nibbling pattern (3 to 5 meals daily)
Study: 3535005
Drug: Ranitidine (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine (150 mg twice daily) for 6 months
Study: 3535005
Drug: Short-term treatment
Normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Short-term treatment with ranitidine
Study: 25316451
Drug: Daily emotional
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily emotional monitoring
Study: 22389428
Drug: Rimonabant (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rimonabant (20 mg/day) plus lifestyle counselling
Study: 19531931
Drug: DPSGC 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: DPSGC 50 mg
Study: 20187842
Drug: DPSGC 25
Approvals — FDA: no, EMA: no, PMDA: no
Description: DPSGC 25 mg and 50 mg
Study: 16274480
Drug: Dexamethasone (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone (8 mg prophylactic and 4 mg postoperative IV) and Diclofenac potassium (50 mg oral before and after surgery)
Study: 16274480
Drug: Diclofenac potassium
Normalized name: Diclofenac Potassium
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Diclofenac potassium (50 mg oral before and after surgery)
Study: 11950484
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg ketanserin given as intravenous boluses every 10 min
Study: 11950484
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg ketanserin given as intravenous boluses every 20 min
Study: 10468799
Drug: Maxacalcitol 25
Normalized name: Paricalcitol
DrugBank: Paricalcitol (DB00910)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Maxacalcitol 25 microg/g
Study: 10468799
Drug: Maxacalcitol (6,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maxacalcitol (6, 12.5, 25, and 50 microg/g)
Study: 10468799
Drug: Calcipotriol 50
Normalized name: Calcipotriol 50 microgram/g cutaneous cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcipotriol 50 microg/g
Study: 8678261
Drug: metoclopramide 0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: metoclopramide 0.1 mg.kg‐1
Study: 8678261
Drug: metoclopramide 0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: metoclopramide 0.2 mg.kg‐1
Study: 8678261
Drug: prochlorperazine 0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: prochlorperazine 0.1 mg.kg‐1
Study: 8678261
Drug: prochlorperazine 0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: prochlorperazine 0.2 mg.kg‐1
Study: 2149047
Drug: Teicoplanin (T)
Normalized name: teicoplanin
DrugBank: Teicoplanin (DB06149)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Teicoplanin (T) 6 mg/kg/d and Fluconazole (F) 3 mg/kg/d
Study: 2149047
Drug: Teicoplanin (T)
Normalized name: teicoplanin
DrugBank: Teicoplanin (DB06149)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Teicoplanin (T) 10 mg/kg/d, Ceftriaxone (C) 50 mg/kg/d, and Amikacin (A) 15 mg/kg/d
Study: 379841
Drug: 768 mg
Normalized name: butyl chloride 1768 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 768 mg chlormethiazole
Study: 28724331
Drug: Balanites aegyptiaca
Normalized name: BALANITES AEGYPTIACA SEED OIL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Balanites aegyptiaca (BE) capsules (400mg/day) for 8 weeks
Study: 26669547
Drug: 5 or
Normalized name: Acys-5 Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 or 6 mm-long implants
Study: 26669547
Drug: 10 mm-long
Normalized name: LONG PEPPER
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mm-long implants
Study: 24424409
Drug: Intravitreal ranibizumab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal ranibizumab 0.5 mg, 3-month loading phase with monthly injections, followed by a 12-month maintenance phase.
Study: 22940437
Drug: EHCSS-K6 (5mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: EHCSS-K6 (5mg tar, 0.3mg nicotine, and 0.6 mg CO)
Study: 22940437
Drug: EHCSS-K3 (3mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: EHCSS-K3 (3mg tar, 0.2mg nicotine, and 0.6 mg CO)
Study: 17138937
Drug: Argatroban (350
Approvals — FDA: no, EMA: no, PMDA: no
Description: Argatroban (350 microg/kg intravenous bolus followed by 25 microg/kg per minute infusion)
Study: 17138937
Drug: Enoxaparin (0.75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoxaparin (0.75 mg/kg, intravenous bolus)
Study: 11318292
Drug: Topical cyclosporin
Normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical cyclosporin A (CsA)
Study: 2965231
Drug: Isradipine (5.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isradipine (5.1 mg twice daily)
Study: 29535504
Drug: HTX-019 (130
Approvals — FDA: no, EMA: no, PMDA: no
Description: HTX-019 (130 mg) IV over 30 min
Study: 29535504
Drug: Fosaprepitant (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fosaprepitant (150 mg) IV over 30 min
Study: 25065855
Drug: Intravenous iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous iron sucrose (200 mg weekly for 5 weeks)
Study: 17411338
Drug: Antiretroviral therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiretroviral therapy (ART) including protease inhibitor or non-nucleoside reverse transcriptase inhibitor
Study: 12221873
Drug: N2O:O2 (70:30)
Approvals — FDA: no, EMA: no, PMDA: no
Description: N2O:O2 (70:30) + phentanyl (0.1 ml boluses every 20 min)
Study: 10076584
Drug: Food label
Normalized name: Take With Food Label
Approvals — FDA: no, EMA: no, PMDA: no
Description: Food label education program (9 weekly group sessions)
Study: 7367779
Drug: Intranasal beclomethasone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal beclomethasone dipropionate aerosol (BDA)
Study: 17255296
Drug: Neoadjuvant therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant therapy in the metastatic setting
Study: 17255296
Drug: Neoadjuvant strategies
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant strategies integrating aggressive surgical intervention with systemic therapy
Study: 15119639
Drug: Early start
Normalized name: Star Anise Oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Early start dialysis (10-14 mL/min/1.73 m2)
Study: 15119639
Drug: Late start
Normalized name: Star Anise Oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Late start dialysis (5-7 mL/min/1.73 m2)
Study: 11268891
Drug: Fusidic acid
Normalized name: Fusidic acid
DrugBank: Fusidic acid (DB02703)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fusidic acid 500 mg twice a day for 7.5 days
Study: 11268891
Drug: Pristinamycin 1
Normalized name: pristinamycin
DrugBank: Pristinamycin (DB13704)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pristinamycin 1 g twice a day for 10 days
Study: 3935853
Drug: Antibiotic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic treatment (cephalosporin treatment alone: cefotaxime, cefazolin)
Study: 3935853
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of two or three antibiotics
Study: 3935853
Drug: Wider antibiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wider antibiotic spectrum
Study: 29486504
Drug: Hippotherapy (once
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hippotherapy (once to twice weekly for 16 to 20 weeks, mean: 17 treatments)
Study: 29486504
Drug: Hippotherapy (early
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hippotherapy (early treatment group)
Study: 25312315
Drug: Platelet rich
Normalized name: Platelet Rich Plasma
DrugBank: Platelet Rich Plasma (DB19295)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Platelet rich plasma (5 mL in two applications)
Study: 25312315
Drug: Oral paracetamol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral paracetamol (1 gr every 8 hours for 30 days)
Study: 17660520
Drug: Remifentanil at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil at 1 ng ml(‐1)
Study: 17660520
Drug: Remifentanil at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil at 3 ng ml(‐1)
Study: 17660520
Drug: Remifentanil at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil at 5 ng ml(‐1)
Study: 14732596
Drug: High-dose glycine
Normalized name: Glycine
DrugBank: Glycine (DB00145)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: High-dose glycine (0.8 g/kg/day)
Study: 10730723
Drug: Preventive oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preventive oral hygiene program including instruction of the carers and implementation of a recall program for professional oral hygiene care
Study: 10730723
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no preventive oral hygiene program)
Study: 8831317
Drug: 1.73% lidocaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.73% lidocaine with 10 micrograms/mL of clonidine (Group C10)
Study: 8831317
Drug: 1.73% lidocaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.73% lidocaine (Group L)
Study: 8831317
Drug: 1.73% lidocaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.73% lidocaine with 20 micrograms/mL clonidine (Group C20)
Study: 1279289
Drug: Terbutaline (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terbutaline (5 mg three times daily)
Study: 1279289
Drug: Ketotifen (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketotifen (1 mg twice daily) with Terbutaline
Study: 30706247
Drug: T-DM1 (3.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: T-DM1 (3.6 mg/kg q3w, 2.4 mg/kg qw)
Study: 30706247
Drug: T-DM1 (2.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: T-DM1 (2.4 mg/kg qw)
Study: 21937808
Drug: Laparoscopic splenectomy,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Laparoscopic splenectomy, perisoph‐agogastric devascularization and endoscopic variceal ligation (combination group)
Study: 19155351
Drug: Percutaneous intramuscular
Normalized name: PERCUTANEOUS INTRODUCER SET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Percutaneous intramuscular electrical stimulation for hand opening (n = 13)
Study: 15019537
Drug: Vitamin E
Normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vitamin E (500 mg/day)
Study: 15019537
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of fenofibrate and Vitamin E
Study: 9188228
Drug: Dental implants
Normalized name: Drug Implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dental implants
Study: 12500879
Drug: Natural teeth
Approvals — FDA: no, EMA: no, PMDA: no
Description: Natural teeth and implants
Study: 9141204
Drug: 20 micrograms
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 micrograms Engerix-B vaccine
Study: 9141204
Drug: 40 micrograms
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 micrograms Engerix-B vaccine
Study: 3436158
Drug: 1 g
Normalized name: Molds 1 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g aztreonam
Study: 30796598
Drug: New peanut
Approvals — FDA: no, EMA: no, PMDA: no
Description: New peanut allergen treatment
Study: 30412221
Drug: Induction chemotherapy
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction chemotherapy (IC) with TPF (docetaxel, cisplatin, 5-FU omitted in subsequent patients) followed by radiotherapy (69.6 Gy)
Study: 30412221
Drug: Cetuximab added
Normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Cetuximab added to induction chemotherapy (IC) with TPF followed by radiotherapy (69.6 Gy)
Study: 30412221
Drug: Induction chemotherapy
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction chemotherapy (IC) with TPF followed by radiotherapy (69.6 Gy)
Study: 22377815
Drug: Propranolol LA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol LA (240 mg/day)
Study: 22377815
Drug: Topiramate alone
Normalized name: Topiramate
DrugBank: Topiramate (DB00273)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Topiramate alone (50-100 mg/day)
Study: 19615827
Drug: TSST administered
Normalized name: no vaccine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: TSST administered prior to compassion meditation training
Study: 16006194
Drug: Omega-3 fatty
Normalized name: Omega-3 fatty acid
DrugBank: Omega-3 fatty acids (DB11133)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omega-3 fatty acid supplementation (1 g eicosapentaenoic acid (EPA) and 0.7 g docosahexaenoic acid (DHA) daily)
Study: 8725038
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg BCG therapy
Study: 8725038
Drug: 80 mg
Normalized name: RNA 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 mg BCG therapy
Study: 352142
Drug: Duck Embryo
Normalized name: Duck
DrugBank: Duck (DB10610)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Duck Embryo Vaccine (DEV), 4 doses
Study: 352142
Drug: WI-38 Vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: WI-38 Vaccine (WRV), 4 doses
Study: 352142
Drug: WI-38 Vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: WI-38 Vaccine (WRV), 2 doses
Study: 352142
Drug: WI-38 Vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: WI-38 Vaccine (WRV), 3 or 4 doses
Study: 31029515
Drug: 10-10-PLAIN (non-adjuvanted
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10-10-PLAIN (non-adjuvanted formulation)
Study: 31029515
Drug: 10-10-AS01 (AS01-adjuvanted
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10-10-AS01 (AS01-adjuvanted formulation with 10 µg of each antigen)
Study: 31029515
Drug: 10-3-AS01 (AS01-adjuvanted
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10-3-AS01 (AS01-adjuvanted formulation with 10 µg of each NTHi antigen and 3.3 µg of Mcat antigen)
Study: 26488693
Drug: Nicotinamide 500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicotinamide 500 mg twice daily
Study: 17077229
Drug: CDB‐2914 (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: CDB‐2914 (50 mg single dose)
Study: 17077229
Drug: Levonorgestrel (0.75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levonorgestrel (0.75 mg two doses taken 12 hours apart)
Study: 15039761
Drug: Sustained release
Normalized name: Sustained Release Buccal Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustained release d‐amphetamine (escalating 15‐30 or 30‐60 mg)
Study: 15039761
Drug: Risperidone (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risperidone (2 or 4 mg)
Study: 9097530
Drug: Ivermectin (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ivermectin (100 micrograms/kg, two single doses, 3 months apart)
Study: 26386381
Drug: Honey based
Normalized name: honey based topical applications
Approvals — FDA: no, EMA: no, PMDA: no
Description: Honey based formulation of Nigella sativa seed oil (5 ml N. sativa oil orally daily) for 8 weeks
Study: 23000726
Drug: Tulobuterol patches
Normalized name: tulobuterol
DrugBank: Tulobuterol (DB12248)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tulobuterol patches (1-2mg daily)
Study: 23000726
Drug: Theophylline (4-5mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Theophylline (4-5mg/kg daily)
Study: 19087899
Drug: TSD and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: TSD and paroxetine treatment
Study: 19087899
Drug: TSD and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: TSD and 2 weeks of placebo followed by paroxetine treatment
Study: 19087899
Drug: 2 weeks
Normalized name: Rykindo, 25 mg/2 weeks intramuscular powder for injection, extended release
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 weeks of paroxetine treatment